A randomized controlled trial for the use of Thymus Honey in decreasing Salivary Gland Damage following Radioiodine Therapy for Thyroid cancer: Research protocol

Journal of Advanced Nursing

Volumn 70, Issue 7, 2014, Pages 1663-1671

  Charalambous, Andreas ^a   Frangos, Savvas ^b   Talias, Michalis ^c  

^a CYPRUS UNIVERSITY OF TECHNOLOGY   (Cyprus)

^b Bank of Cyprus Group Oncology Centre   (Cyprus)

^c OPEN UNIVERSITY OF CYPRUS   (Cyprus)

Author keywords

Nurse; Quality of life; Radioiodine; Sialadenitis; Thyroid cancer; Xerostomia

Indexed keywords

MOUTHWASH; RADIOACTIVE IODINE;

CONTROLLED STUDY; HUMAN; RADIATION RESPONSE; RANDOMIZED CONTROLLED TRIAL; SALIVARY GLAND; THYROID NEOPLASMS;

HUMANS; IODINE RADIOISOTOPES; MOUTHWASHES; SALIVARY GLANDS; THYROID NEOPLASMS;

EID: 84901932253     PISSN: 03092402     EISSN: 13652648     Source Type: Journal    
DOI: 10.1111/jan.12318     Document Type: Article

References (48)

1. Almeida J.P., Sanabria A.E., Lima E.N., Kowalski L.P. & LP. (2011) Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer. Head and Neck 33, 686-690.
2. Ball D.W. (2007) The chemical composition of honey. Journal of Chemical Education 84(10), 1643.
3. Becker D.V. & Hurley J.R. (1995) Treatment of thyroid cancer with radioiodine (131I). In: Diagnostic Nuclear Medicine, 3rd edn (Sandler M.P., Patton J.A., Coleman R.E., Gottschalk A., Wackers F.J. & Hoffer P.B. eds), Williams & Wilkins, Baltimore, pp. 959-989.
4. Bohsulavizki K.H., Brenner W., Klutmann S., Hubner R.H., Lassmann S., Feyerabend B., Lutgges J., Tinnemeyer S., Clausen M. & Henze E. (1998) Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy. Journal of Nuclear Medicine 39, 1237-1242.
5. Bohuslavizki K.H., Brenner W. & Lassmann S. (1996) Quantitative salivary gland scintigraphy in the diagnosis of parenchymal damage after radioiodine [Abstract]. European Journal of Nuclear Medicine 23, 1062.
6. Bohuslavizki K.H., Brenner W., Tinnemeyer S., Kallina S., Clausen M. & Henze E. (1997) Is quantitative salivary gland scintigraphy a mandatory examination prior to and after radioiodine therapy. Radiation Oncology 31, 5-12.
7. Bushnell D.L., Boles M.A., Kaufman G.E., Wadas M.A. & Barnes W.E. (1992) Complications, sequela and dosimetry of iodine-131 therapy for thyroid carcinoma. Journal of Nuclear Medicine 33, 2214-2221.
8. Charalambous M., Raftopoulos V., Lambrinou E. & Charalambous A. (2013) The effectiveness of honey for the management of radiotherapy-induced mucositis in head and neck patients: a systematic review of RCT. European Journal of Integrative Medicine 5(3), 217-225.
9. Chow S.M., Yau S., Kwan C.K., Poon P.C. & Law S.C. (2006) Local and regional control in patients with papillary thyroid carcinoma: specific indications of external radiotherapy and radioactive iodine according to T and N categories in AJCC, 6th edition. Endocrine-Related Cancer 13(4), 1159-1172.
10. DeGroot I.J., Larsen P.R. & Hennemann G. (1996) The Thyroid and Its Diseases, 6th edn. Churchill Livingstone, New York, pp. 658-696.
11. Dirix P., Nuyts S., Poorten V.V., Delaere P. & Bogaert W.V. (2007) Efficacy of the Bioxtra dry mouth care system in the treatment of radiotherapy-induced xerostomia. Supportive Care in Cancer 15, 1429-36.
12. Dunford C., Cooper R. & Molan P. (2000) Using honey as a dressing for infected skin lesions. Nurs Times 96(14 Suppl), 7-9.
13. Ediriweera E.R.H.S.S. & Premarathna N.Y.S. (2012) Medicinal and cosmetic uses of Bee's Honey - A review. AYU (An International Quarterly Journal of Research in Ayurveda) 33(2), 178-182.
14. Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., Rosso S., Coebergh J.W.W., Comber H., Forman D. & Bray F. (2012) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. European Journal of Cancer 49, 1374-1403.
15. Grewal R.K., Larson S.M., Pentlow C.E., Pentlow K.S., Gonen M., Qualey R., Natbony L. & Tuttle M.R. (2009) Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation. Journal of Nuclear Medicine 50, 1605-1610.
16. Groenvold M. & Klee M.C. (1997) Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement. Journal of Clinical Epidemiology 50(4), 441-450.
17. Haymart M.R., Banerjee M., Stewart A.K., Koenig R.J., Birkmeyer J.D. & Griggs J.J. (2011) Use of radioactive iodine for thyroid cancer. Journal of the American Medical Association 306(7), 721-728.
18. Howlader N., Noone A.M., Krapcho M., Garshell J., Neyman N., Altekruse S.F., Kosary C.L., Yu M., Ruhl J., Tatalovich Z., Cho H., Mariotto A., Lewis D.R., Chen H.S., Feuer E.J. & Cronin K.A. (2013) SEER Cancer Statistics Review, 1975-2010. National Cancer Institute, Bethesda, MD. Retrieved from http://seer.cancer.gov/csr/1975_2010/ on 10th April 2013.
19. Johannsson L., Mattsson S., Nosslin B. & Leide-Svegborn S. (1992) Effective dose from radiopharmaceuticals. European Journal of Nuclear Medicine 19, 933-938.
20. Jung T.S., Kim T.Y. & Kim K.W. (2007) Clinical features and prognostic factors for survival in patients with poorly differentiated thyroid carcinoma and comparison to the patients with the aggressive variants of papillary thyroid carcinoma. Endocrine Journal 54(2), 265-274.
21. Kita T., Yokoyama K., Higuchi T., Kinuya S., Taki J., Nakajima K., Michigishi T. & Tonami N. (2004) Multifactorial analysis on the short-term side effects occurring within 96 hours after radioiodine-131 therapy for differentiated thyroid carcinoma. Annals of Nuclear Medicine 18, 345-349.
22. Klubo-Gwiezdzinska J., Van Nostrand D., Burman K.D., Vasko V., Chia S., Deng T., Kulkarni K. & Wartofsky L. (2010) Salivary gland malignancy and radioiodine therapy for thyroid cancer. Thyroid 20(6), 647-651.
23. Klutmann S., Bohuslavizki K.H., Kroger S., Bleckmann C., Brenner W., Mester J. & Clausen M (1999) Quantitative salivary gland scintigraphy. Nuclear Medicine Technology 27, 20-26.
24. Lee S.L. (2010) Complications of radioactive iodine treatment of thyroid carcinoma. Journal of the National Comprehensive Cancer Network 8(11), 1277-1286.
25. Levenson D., Gulec S., Sonenberg M., Lai E., Goldsmith S.J. & Larson S.M. (1994) Peripheral facial nerve palsy after high-dose radioiodine therapy in patients with papillary thyroid carcinoma. Annals of Internal Medicine 120, 576-578.
26. LeVeque F.G., Montgomery M., Potter D., Zimmer M.B., Rieke J.W., Steiger B.W., Gallagher S.C. & Muscoplat C.C. (1993) A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. Journal of Clinical Oncology 11, 1124-1131.
27. Loveridge J. (2001) The chemistry of Bees. Retrieved from http://www.chm.bris.ac.uk/webprojects2001/loveridge/index-page3.html on 18 March 2013.
28. Lusby P.E., Coombes A. & Wilkinson J.M. (2002) Honey: a potent agent for wound healing? Journal of Wound, Ostomy and Continence Nursing 29, 295-300.
29. Luster M., Clarke S.E., Dietlein M., Lassmann M., Lind P., Oyen W.J.G., Tennvall J. & Bombardier E. (2008) Guidelines for radioiodine therapy of differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging 35(10), 1941-1959.
30. Ma C., Xie J., Chen Q., Wang G. & Zuo S. (2009) Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer. The Cochrane Database of Systematic Reviews 4, CD007956.
31. Mandel S.J. & Mandel L. (2003) Radioactive Iodine and the Salivary Glands. Thyroid 13(3), 265-271.
32. Mazzaferri E. (2000) Carcinoma of the follicular epithelium. In: Werner and Ingbar's The Thyroid (Braverman L.E. & Utiger R.D., eds), Lippincott, Philadelphia, PA, pp. 904-929.
33. McDougall R.I. (1992) Thyroid Disease in Clinical Practice. Chapman & Hall, London, UK, pp. 215-230.
34. Moher D., Schulz K.F. & Altman D.G. (2001) The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. Lancet 357, 1191-1194.
35. Moore O.A., Smith L.A., Campbell F., Seers K., McQuay H.J. & Moore R.A. (2001) Systematic review of the use of honey as a wound dressing. BMC Complementary and Alternative Medicine 1(1), 2.
36. Nakada K., Ishibashi T., Takei T., Hirata K., Shinohara K., Katoh S., Zhao S., Tamaki N., Noguchi Y. & Noguchi S. (2005) Does Lemon Candy Decrease Salivary Gland Damage After Radioiodine Therapy for Thyroid Cancer? Journal of Nuclear Medicine 46, 261-266.
37. Newkirk K.A., Ringel M.D., Wartofsky L. & Burman K.D. (2000) The role of radioactive iodine in salivary gland dysfunction. Ear, Nose, and Throat Journal 79, 460-468.
38. Olaitan P.B., Adeleke O.E. & Ola I.O. (2007) Honey: a reservoir for microorganisms and an inhibitory agent for microbes. The African Journal of Health Sciences 7(3), 159-165.
39. Pellegriti G., Giuffrida D. & Scollo C. (2002) Long-term outcome of patients with insular carcinoma of the thyroid: the insular histotype is an independent predictor of poor prognosis. Cancer 95, 2076-2085.
40. Silberstein E.B. (2008) Reducing the incidence of 131i-induced sialadenitis: the role of pilocarpine. Journal of Nuclear Medicine 49, 546-549.
41. Sisson J.C., Freitas J., McDougall R.I., Dauer L.T., Hurley J.R., Brierley J.D., Edinboro C.H., Rosenthal D., Thomas M.J., Wexler J.A., Asamoah E., Avram A.M., Milas M. & Greenlee C. (2011) Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroiad Association. Thyroid 21(4), 335-346.
42. Solans R., Bosch J.A., Galofre P., Porta F., Roselló J., Selva-O'Callagan A. & Vilardell M. (2001) Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. Journal of Nuclear Medicine 42, 738-743.
43. Stephen-Haynes J. (2004) Evaluation of a honey -impregnated tulle dressing in primary care. British Journal of Community Nursing Supplement 9, S21-S27.
44. Tuttle R.M., Brokhin M. & Omry G. (2008) Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. Journal of Nuclear Medicine 49, 764.
45. Volante M., Landolfi S., Chiusa L., Palestini N., Motta M., Codegone A., Torchio B. & Papotti M.G. (2004) Poorly differentiated carcinomas of the thyroid with trabecular, insular and solid patterns: a clinicopathologic study of 183 patients. Cancer 100, 950-957.
46. Walter M.A., Turtschi C.P., Schindler C., Minnig P., Jan Muller-Brand J.M. & Beat Muller B. (2007) The dental safety profile of high-dose radioiodine therapy for thyroid cancer: long-term results of a longitudinal cohort study. Journal of Nuclear Medicine 48, 1620-1625.
47. Wartofsky L. (2000) Thyroid Cancer: A Comprehensive Guide to Clinical Management. Humana Press, Totowa, NJ, pp. 155-162.
48. Wolski T., Tambor K., Rybak-Chmielewska H. & Kedzia B. (2006) Identification of honey volatile components by solid phase microextraction (SPME) and gas chromatography/mass spectrometry (GC/MS). Journal of Apicultural Science 50(2), 115-126.